Abstract 1686: TSC2 enhances antitumor immunity and potentiates PD-1 and CTLA-4 blockade
Heng-Jia Liu(Brigham and Women's Hospital), Elizabeth P. Henske(Brigham and Women's Hospital), Kwok‐Kin Wong(NYU Langone Health), Heng Du(Brigham and Women's Hospital), Arlene H. Sharpe(Brigham and Women's Hospital), Patrick H. Lizotte(Harvard University), Spencer Vaughan(Brigham and Women's Hospital), Maria C. Speranza(Dana-Farber Cancer Institute), Gordon J. Freeman(Dana-Farber Cancer Institute), Nicola Alesi(Brigham and Women's Hospital)
Cited by 2
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|2.9k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
|The Journal of Experimental Medicine|2009|2k